Applications of Dye‐sensitized Photoreactions in Neurobiology

Spikes, John D.

doi:10.1111/j.1751-1097.1991.tb02132.x

Cited by 38 publications

(30 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, during clinical use this product showed a number of serious drawbacks, namely, a long biological half-life (several weeks), insufficient accumulation in tumors, short absorption wavelength (630 nm), as well as difficult isolation of individual components (the hematoporphirin derivative is a mixture of monomeric and polymeric porphyrins) [42][43][44][45]. Therefore, research into the development of more advanced photosensitizers of the next generation was initiated.…”

Section: Photosensitizers Their Photophysical and Photochemical Propmentioning

confidence: 98%

New medicines and approaches to treatment of atherosclerosis

et al. 2012

View full text Add to dashboard Cite

Prerequisites for the use of photodynamic therapy (PDT) to treatment of atherosclerosis, as well as the development and structure of atherosclerotic vascular lesions in humans are analyzed. The basic requirements for PDT components, specifically photosensitizers (PS), and the radiation source, and the current state of their development are overviewed. Some original results of in vitro studies of the effect of PS on the basis of phthalocyanines and radiation on cells from the atherosclerotic plaques are presented.

show abstract

Section: Photosensitizers Their Photophysical and Photochemical Propmentioning

confidence: 98%

New medicines and approaches to treatment of atherosclerosis

et al. 2012

View full text Add to dashboard Cite

show abstract

“…PDT consists of the administration and selective accumulation of a PS in tumor target tissues, followed by generation of singlet oxygen ( 1 O 2 ) and other cytotoxic reactive oxygen species (ROS) that result in cell membrane damage and subsequent cell death upon light irradiation with an appropriate wavelength in the presence of tissue oxygen. [8][9][10][11][12] However, the first generation PS, Photofrin ® has some disadvantages due to side effects, including sub-optimal tumor selectivity, 13 low absorption intensity of light and poor light penetration into the tumor due to the relatively short wavelength absorption (630 nm), 14 prolonged skin photosensitivity in patients, 15 and the fact that it is a complex mixture of uncertain structure. 16,17 Therefore, to overcome these drawbacks and to improve the treatment efficacy, some second generation PSs have been developed and are under clinical trials.…”

Section: Introductionmentioning

confidence: 99%

Ionic Liquid-Based Chlorins and Type III Mechanism of Photodynamic Therapy (PDT)

Yoon¹,

Demberelnyamba²,

Li³

et al. 2014

Handbook of Porphyrin Science

View full text Add to dashboard Cite

“…The photochemically-induced permanent ischemia model utilizes a systemic injection of the photo-sensitive dye, Rose Bengal, followed by cerebral exposure to a light source to induce injury. Rose Bengal has been shown to penetrate into the cytoplasm as well as bind cell membranes and after absorbing photons induces oxidation of membrane components [22,23]. The oxidation leads to abnormal endothelial function, platelet activation, platelet aggregation, and thrombus formation [24,25].…”

Section: Introductionmentioning

confidence: 99%

The CB1 antagonist, SR141716A, is protective in permanent photothrombotic cerebral ischemia

Reichenbach

Ward

et al. 2016

Neuroscience Letters

View full text Add to dashboard Cite

Modulation of the endocannabinoid system has been shown to have a significant impact on outcomes in animal models of stroke. We have previously reported a protective effect of the CB1 antagonist, SR141716A, in a transient reperfusion mouse model of cerebral ischemia. This protective effect was in part mediated by activation of the 5HT1A receptor. Here we have examined its effect in a mouse model of permanent ischemia induced by photoinjury. The CB1 antagonist was found to be protective in this model. As was the case following transient ischemia reperfusion, SR141716A (5 mg/kg) resulted in smaller infarct fractions and stroke volumes when utilized both as a pretreatment and as a post-treatment. In contrast to the effect in a transient ischemia model, the pretreatment effect did not depend on the 5HT1A receptor. Neurological function correlated favorably to the reduction in stroke size when SR141716A was given as a pretreatment. With the incidence of stroke predicted to rise in parallel with an ever aging population, understanding mechanisms underlying ischemia and therapeutics remains a paramount goal of research.

show abstract

Applications of Dye‐sensitized Photoreactions in Neurobiology

Cited by 38 publications

References 104 publications

New medicines and approaches to treatment of atherosclerosis

New medicines and approaches to treatment of atherosclerosis

Ionic Liquid-Based Chlorins and Type III Mechanism of Photodynamic Therapy (PDT)

The CB1 antagonist, SR141716A, is protective in permanent photothrombotic cerebral ischemia

Contact Info

Product

Resources

About